CORZ — Core Scientific Cashflow Statement
0.000.00%
Last trade - 00:00- $2.45bn
- $2.71bn
- $510.67m
- 36
- 50
- 19
- 27
Annual cashflow statement for Core Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.2 | 47.3 | -2,146 | -246 | -1,315 |
| Depreciation | |||||
| Non-Cash Items | 0.161 | -87.9 | 1,648 | -335 | 1,272 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -21.1 | -49.5 | 479 | 551 | -27.6 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -23.8 | -56.7 | 205 | 65.1 | 42.9 |
| Capital Expenditures | -15.2 | -424 | -602 | -17 | -95.2 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | 0.092 | 0.645 | 10.9 | 14 | 0 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -15.1 | -424 | -591 | -3 | -95.2 |
| Financing Cash Flow Items | — | -10.7 | 163 | 0 | -7.24 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 40.7 | 604 | 306 | -44.6 | 820 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.81 | 123 | -79.4 | 17.5 | 767 |